SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Update

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) saw a large growth in short interest in October. As of October 31st, there was short interest totalling 8,610,000 shares, a growth of 41.6% from the October 15th total of 6,080,000 shares. Based on an average daily volume of 535,900 shares, the short-interest ratio is currently 16.1 days.

SELLAS Life Sciences Group Price Performance

Shares of SLS stock traded up $0.05 on Friday, hitting $1.32. The company’s stock had a trading volume of 861,803 shares, compared to its average volume of 1,071,800. The stock has a market capitalization of $84.92 million, a price-to-earnings ratio of -1.91 and a beta of 2.39. SELLAS Life Sciences Group has a fifty-two week low of $0.50 and a fifty-two week high of $1.72. The firm’s fifty day moving average price is $1.23 and its 200-day moving average price is $1.26.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. Analysts predict that SELLAS Life Sciences Group will post -0.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC bought a new position in SELLAS Life Sciences Group in the 2nd quarter worth approximately $39,000. XTX Topco Ltd acquired a new stake in shares of SELLAS Life Sciences Group in the third quarter worth $78,000. State Street Corp increased its position in SELLAS Life Sciences Group by 30.2% during the third quarter. State Street Corp now owns 174,529 shares of the company’s stock worth $218,000 after acquiring an additional 40,500 shares during the period. Geode Capital Management LLC raised its stake in SELLAS Life Sciences Group by 17.1% during the 3rd quarter. Geode Capital Management LLC now owns 605,191 shares of the company’s stock valued at $757,000 after purchasing an additional 88,183 shares during the last quarter. Finally, Anson Funds Management LP bought a new stake in SELLAS Life Sciences Group in the 3rd quarter valued at $992,000. Institutional investors and hedge funds own 17.38% of the company’s stock.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.